Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber Cancer Institute has agreed to pay $15 million to the U.S. government in a settlement to resolve allegations that, between 2014 and 2024, Dana-Farber violated the False Claims Act by “using fraudulent images in grant applications and research articles to induce the NIH to pay millions of dollars to support research at Dana-Farber.”

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.

October 03, 2025

Vol.51 No.36

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.

September 12, 2025

Vol.51 No.33

Cancer Policy

Trump administration unlawfully terminated grants from Harvard, federal judge rules

A federal judge ruled that the Trump Administration’s move to cut research funding to Harvard University was illegal—restoring more than $2 billion and all future grants to the institution.

Columbia settles with Trump, agreeing to a $200M fine, as Harvard fights on

It has been more than three months since the Trump Administration froze Columbia University’s NIH funds in an attempt to crack down on “antisemitism.”

July 25, 2025

Vol.51 No.29

By Claire Marie Porter and Jacquelyn Cobb

Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history

YOU MAY BE INTERESTED IN

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Trump administration unlawfully terminated grants from Harvard, federal judge rules

Columbia settles with Trump, agreeing to a $200M fine, as Harvard fights on

Renew today!

Subscriber content

Never miss an issue!

Login

Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history

YOU MAY BE INTERESTED IN

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Trump administration unlawfully terminated grants from Harvard, federal judge rules

Columbia settles with Trump, agreeing to a $200M fine, as Harvard fights on

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”